Skip to main content

5 Questions with TMC Innovation Institute Director Tom Luby

Published Apr 15, 2019 by Maggie Martin

 

TMC Innovation Institute

 

Tom Luby was recently named director of the Texas Medical Center Innovation Institute. Luby previously headed up JLABS @ TMC.

Below, Luby shares his priorities, what he's looking forward to most this year and how the institute fits in with the rest of Houston's innovation ecosystem. 

What are your priorities as Director of the Texas Medical Center Innovation Institute?

The Texas Medical Center’s goal is to serve its 61 [institution] members, and everything we do stems from that. At the TMC Innovation Institute, we’re focused on attracting companies from around the globe and showing them the value of establishing a presence in the largest medical city in the world. We want to work with those companies, open doors for them and provide them with solutions that will meet their needs.

We are continuing to build upon the success of TMC Biodesign, our fellowship program that unites the talents of innovators in order to quickly bring breakthrough products to market. And, of course, we will continue to grow our signature TMCx accelerator program, which provides startup companies with shared workspace, a curriculum for entrepreneurs and access to more than 200 advisors. We've had more than 250 companies come through the Innovation Institute that have received more than $900 million in funding, so we’re doing well. But I’m eager to add even more fuel to that fire. 

We also want to engage with corporate partners and believe it’s critical that major health care companies establish significant footprints in Houston. Importantly, we’re also working to bring more startup capital to Houston, which is critical to fostering the success of early-stage companies in Houston. 

What are the projects and initiatives you’re excited for most this year? 

This summer, we will open TMCxi at our John P. McGovern Campus on Holcombe Boulevard. It will be nearly 25,000 square feet of Class A office space that provides a turnkey solution for industry partners who seek to establish a presence in our growing health care ecosystem.

We see TMCxi as an amazing resource for technology companies, venture capitalists and others who want to be in the heart of the Texas Medical Center. It’s an important part of the TMC Innovation Institute, and we’re eager to welcome our new partners here. 

Why is innovation in health care—and at the TMC—so important? 

It’s important that we always remember: it’s all about the patients. We have a growing population of older adults, and we all know that end-of-life health care tends to be the most expensive. We need solutions that will provide people with the opportunity to live longer, healthier, high-quality lives, and hopefully prevent them from becoming long-term patients. 

When we talk about innovation, we often talk about devices, but we’re also talking about other forms of innovation. We want to see innovation in the way that health care is packaged and delivered too. Health care is expensive, and it needs to be more efficient. We think innovation means addressing those challenges as well. 

How does your organization fit into Houston as a growing innovation hub?

The TMC Innovation Institute is on the leading edge of Houston’s growing health care startup ecosystem. Our job is to enable our members to more efficiently turn their work in basic science and translational research into new products that will ultimately help patients. It’s also to connect our members to the startups that are developing the tools they need to continue providing world-class, cutting-edge health care. Additionally, our role is to recruit health care capital that can provide the crucial funding startups need to deliver on the promise of innovation.

We are engaging with large health care companies and showing them the tremendous value of establishing a presence in a place that’s home to 9,000-plus patient beds and some of the top researchers and clinicians from around the world. Importantly, we recognize that top talent has the opportunity to work anywhere, so we continue to play a key role in recruiting the world’s best to the Texas Medical Center.

The TMC Innovation Institute’s vision is “to become the global leader in health and life science innovation.” How do you envision meeting that goal?

We’re going to continue pushing to grow and develop that startup ecosystem here. We’ll be working with our member institutions to do that, as well as other partners in the startup space here in Houston. There is so much momentum right now. I think it’s increasingly clear to the world that if you’re a health care startup, you really need to have a foothold in the Texas Medical Center.

I keep saying this, but that’s because it’s so important. A big part of accomplishing our goals will require more and more startup capital to invest in early-stage companies in Houston. We’re putting our money where our mouth is and investing $25 million in early-stage companies through the TMC Venture Fund. It’s our job to continue drawing the talent here, and to show the value of investing in our ecosystem. If you’re a venture capitalist or corporate partner interested in what’s happening in our health care startup ecosystem — come see us. 

Related News

Life Sciences

MD Anderson, Rice University Launch New Collaborative to Advance Cancer Research

7/2/24
A new collaboration between The University of Texas MD Anderson Cancer Center and Rice University promises to drive industry growth and advance life-saving technologies through the newly established Cancer Bioengineering Collaborative. The initiative will help foster collaboration between the two institutions on fundamental and translational cancer research, develop new technologies for cancer detection and therapy, and secure external funding in support of further research and training. Rice researcher and Cancer Prevention and Research Institute of Texas (CPRIT) scholar Gang Bao and MD Anderson’s Dr. Jeffrey Molldrem will lead the hub.  “From fundamental discoveries in cancer science, tumor immunology and patient care to innovative engineering advances in drug delivery systems, nanostructures and synthetic biology, there is great potential for enabling cross-disciplinary collaboration to develop new technologies and approaches for detecting, monitoring and treating cancer,” Molldrem, chair of Hematopoietic Biology & Malignancy at MD Anderson, said in a release. “Our goal is to bridge the gap between bioengineering and cancer research to create transformative solutions that significantly improve patient outcomes.” The collaborative will also host monthly seminars focused on cancer bioengineering, annual retreats to highlight research and international leaders in cancer and bioengineering. Five research areas will be at the core of the hub’s work: Cell therapies: Developing more effective cell-based immunotherapies, including chimeric antigen receptor- and T cell receptor-based approaches. Nanotechnologies: Using nanoparticles for targeted cancer detection and therapy. Cancer vaccines: Incorporating advanced biomaterials, synthetic biology and nanoparticle delivery systems to develop therapeutic cancer vaccines. Artificial intelligence: Leveraging advanced computing tools for high-precision analysis of samples to identify new targets and inform therapeutic design. Molecular imaging: Deploying advanced molecular imaging techniques to enhance diagnostic and therapeutic tools. A seed grant program will also be established to fund research projects in the early stages of development. The partnership between Rice and MD Anderson is a testament to how the greater Houston region is committed to advancing the life sciences and biotech industry. The region has seen major new life science developments come online recently, including Levit Green, TMC Helix Park and The Alexandria Center for Advanced Technologies in The Woodlands.   
Read More
Life Sciences

The Woodlands Innovation District Aims to Attract Life Sciences Companies

6/28/24
A new district in The Woodlands hopes to expand on the area’s resurgence in life sciences developments.    Post pandemic, life sciences companies have been establishing facilities in The Woodlands, particularly along Research Forest Drive. And now, Developers Howard Hughes and Vitrian are building upon that growth by adding an additional 86.3 acres for future development, aiming to attract more biomanufacturing companies to the area. The duo has dubbed the area The Woodlands Innovation District.  “This joint venture further diversifies the innovative industries that are represented in The Woodlands with the advancement of life science,” said Jim Carman, President of the Houston Region for The Howard Hughes Corporation in a statement. “The Woodlands continues to attract companies from a variety of industries seeking a highly-skilled talent pool, business-friendly environment, and high quality of life for their employees.”  The district joins the area’s cluster of existing life sciences companies, such as Millipore Sigma and VGXI. Cellipont Bioservices, a San Diego-based cell therapy contract development and manufacturing organization, recently opened a 76,000-square-foot facility in the area. The facility is dedicated to cell therapies and serves as the company's new headquarters.  Cellipont’s move to the greater Houston region, announced in 2022, kickstarted a surge in life sciences activity in The Woodlands. Bionova Scientific, another California-based biotech company, recently announced plans to expand into the area, with a 100,000-square-foot manufacturing and research facility. The company, which produces materials used by cancer-fighting cell therapy companies, is expected to begin operations at the new location in 2025.  Nearby, Nurix Therapeutics, a clinical-stage biopharmaceutical company based in San Francisco, has relocated to the Alexandria Center for Advanced Technologies. This 12-acre life sciences campus, formerly the Lexicon Pharmaceuticals site, was inaugurated last year with support from Lexicon’s Founder and CEO and now Nurix's Chief Executive Officer, Arthur Sands. Backed by California-based real estate firm Alexandria Real Estate Equities, the campus is still being built out, with the goal of becoming a smaller version of The Texas Medical Center.   These recent developments have established The Woodlands as a leader in life sciences in the region. According to CBRE’s 2023 U.S. Life Sciences Outlook, The Woodlands accounted for 60% of the Houston region’s life sciences lease transactions in 2022.  The Woodlands Innovation District will encompass five sites, each providing tenant facilities ranging from 40,000 to over 200,000 square feet. These sites will offer build-to-suit shell spaces, anticipated to be move-in ready by Spring 2025.  Learn more about Houston’s life sciences and biotechnology industries. 
Read More

Related Events

Health Care

State of the Texas Medical Center Featuring Life Sciences Summit

The Greater Houston Partnership proudly invites you to the State of the Texas Medical Center and Life Sciences Summit on Thursday, November 14. As the Third Coast for Life Sciences, the region…

Learn More
Learn More
Executive Partners